BR0314183A - 1,4-Diazabicycloalkane derivatives, any of their enantiomers or any mixture of their enantiomers, or a pharmaceutically acceptable addition salt or n-oxide thereof, pharmaceutical composition, use of said compound, any of its enantiomers or any mixture of their enantiomers, or a pharmaceutically acceptable addition salt thereof, and, method of treating, preventing or alleviating a disease or disorder or condition of a living animal body - Google Patents

1,4-Diazabicycloalkane derivatives, any of their enantiomers or any mixture of their enantiomers, or a pharmaceutically acceptable addition salt or n-oxide thereof, pharmaceutical composition, use of said compound, any of its enantiomers or any mixture of their enantiomers, or a pharmaceutically acceptable addition salt thereof, and, method of treating, preventing or alleviating a disease or disorder or condition of a living animal body

Info

Publication number
BR0314183A
BR0314183A BR0314183-7A BR0314183A BR0314183A BR 0314183 A BR0314183 A BR 0314183A BR 0314183 A BR0314183 A BR 0314183A BR 0314183 A BR0314183 A BR 0314183A
Authority
BR
Brazil
Prior art keywords
enantiomers
addition salt
pharmaceutically acceptable
acceptable addition
mixture
Prior art date
Application number
BR0314183-7A
Other languages
Portuguese (pt)
Inventor
Dan Peters
Gunnar M Olsen
Elisebet Ostergaard Nielsen
Tino Dyhring Jorgensen
Philip K Ahring
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Priority claimed from PCT/DK2003/000639 external-priority patent/WO2004029053A1/en
Publication of BR0314183A publication Critical patent/BR0314183A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADO DE 1,4-DIAZABICICLOALCANO, QUAISQUER DE SEUS ENANCIÈMEROS OU QUALQUER MISTURA DE SEUS ENANCIÈMEROS, OU UM SEU SAL DE ADIçãO FARMACEUTICAMENTE ACEITáVEL OU UM SEU N-óXIDO, COMPOSIçãO FARMACêUTICA, USO DO DITO COMPOSTO, DE QUALQUER UM DE SEUS ENANCIÈMEROS OU DE QUALQUER MISTURA DE SEUS ENANCIÈMEROS, OU DE UM SEU SAL DE ADIçãO FARMACEUTICAMENTE ACEITáVEL, E, MéTODO DE TRATAMENTO, PREVENçãO OU ALìVIO DE UMA DOENçA OU UM DISTúRBIO OU CONDIçãO DE UM CORPO ANIMAL VIVO". A invenção refere-se a novos derivados de 1,4-diazabicicloalcano de Fórmula (I): quaisquer de seus enanciómeros ou qualquer mistura de seus enanciómeros, ou um seu sal de adição farmaceuticamente aceitável, ou um seu N-óxido, e seu uso na manufatura de composições farmacêuticas. Os compostos da invenção são verificados como sendo ligandos colinérgicos dos receptores de acetilcolina nicotínica e moduladores dos receptores e transportadores da monoamina. Devido a seu perfil farmacológico, os compostos da invenção podem ser utilizáveis para o tratamento de doenças ou distúrbios tão diversos quanto aqueles relacionados com o sistema colinérgico do sistema nervoso central (CNS), sistema nervoso periférico (PNS), doenças ou distúrbios relacionados com a contração do músculo liso, doenças ou distúrbios endócrinos, doenças ou distúrbios relacionados com a neurodegeneração, doenças e distúrbios relacionados com a inflamação, dor, e sintomas de retirada, causados pela terminação de abuso de substâncias químicas."1,4-DIAZABICYCLOCHANE DERIVATIVE, ANY OF ITS ENANCEMENTS OR ANY MIX OF ITS ENANCYERS, OR A PHARMACEUTICALLY ACCEPTED ADDITION SALT OR N-oxide, COMPOSITION OF A PHARMACEUTICAL OR ANY USE OF A ANY MIX OF ITS FEEDBACK, OR A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT, AND METHOD OF TREATMENT, PREVENTION OR RELIEF OF A LIVING ANIMAL DISEASE OR DISORDER ". The invention relates to novel 1,4-diazabicycloalkane derivatives of Formula (I): any of their enantiomers or any mixture of their enantiomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof, and their use. in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic nicotinic acetylcholine receptor ligands and monoamine receptor modulators and transporters. Due to their pharmacological profile, the compounds of the invention may be usable for the treatment of diseases or disorders as diverse as those related to the cholinergic central nervous system (CNS), peripheral nervous system (PNS), or disease related disorders. smooth muscle contraction, endocrine disorders or disorders, diseases or disorders related to neurodegeneration, diseases and disorders related to inflammation, pain, and withdrawal symptoms, caused by termination of chemical abuse.

BR0314183-7A 2002-09-30 2003-09-29 1,4-Diazabicycloalkane derivatives, any of their enantiomers or any mixture of their enantiomers, or a pharmaceutically acceptable addition salt or n-oxide thereof, pharmaceutical composition, use of said compound, any of its enantiomers or any mixture of their enantiomers, or a pharmaceutically acceptable addition salt thereof, and, method of treating, preventing or alleviating a disease or disorder or condition of a living animal body BR0314183A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201456 2002-09-30
DKPA200201738 2002-11-11
PCT/DK2003/000639 WO2004029053A1 (en) 2002-09-30 2003-09-29 Novel 1,4-diazabicycloalkane derivatives, their preparation and use

Publications (1)

Publication Number Publication Date
BR0314183A true BR0314183A (en) 2005-08-09

Family

ID=34828377

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314183-7A BR0314183A (en) 2002-09-30 2003-09-29 1,4-Diazabicycloalkane derivatives, any of their enantiomers or any mixture of their enantiomers, or a pharmaceutically acceptable addition salt or n-oxide thereof, pharmaceutical composition, use of said compound, any of its enantiomers or any mixture of their enantiomers, or a pharmaceutically acceptable addition salt thereof, and, method of treating, preventing or alleviating a disease or disorder or condition of a living animal body

Country Status (12)

Country Link
JP (1) JP4711391B2 (en)
KR (1) KR20050062575A (en)
CN (1) CN1326857C (en)
BR (1) BR0314183A (en)
HK (1) HK1081954A1 (en)
IL (1) IL166821A (en)
IS (1) IS7829A (en)
MX (1) MXPA05003344A (en)
NO (1) NO20052124L (en)
PT (1) PT1551835E (en)
RU (1) RU2323218C2 (en)
SI (1) SI1551835T1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3019B1 (en) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-Triazoles
BRPI0708843A2 (en) * 2006-05-30 2011-06-14 Neurosearch As compound, pharmaceutical composition, and use of the compound
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
CN101657452A (en) * 2007-02-15 2010-02-24 阿金塔探索有限公司 Hete rocyclic derivatives as the M3 muscarinic receptor
CN106831541B (en) 2011-11-18 2019-09-06 赫普泰雅治疗有限公司 Muscarinic M 1 receptor agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
CA3119019C (en) * 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
CN108727293B (en) * 2016-09-18 2021-05-11 广西师范大学 1,2, 8-oxo diazacyclononane-9-one derivative and synthetic method thereof
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226000A (en) * 1987-09-10 1991-06-25 Merck Sharp & Dohme Oxadiazolyl-azabicycloheptanes and pharmaceutical compositions
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
FR2786770B1 (en) * 1998-12-04 2001-01-19 Synthelabo NONANE 1,4-DIAZABICYCLO [3.2.2.] DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
JP2003504367A (en) * 1999-07-09 2003-02-04 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Neurotrophic pyrrolidines and piperidines, and related compositions and methods
FR2804430B1 (en) * 2000-01-28 2002-03-22 Sanofi Synthelabo 4-HETEROARYL-1,4-DIAZABICYCLO [3.2.2] NONANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2809731B1 (en) * 2000-05-31 2002-07-19 Sanofi Synthelabo 1,4-DIAZABICYCLO- [3.2.2] NONANE-PHEYLISOXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2809732B1 (en) * 2000-05-31 2002-07-19 Sanofi Synthelabo DERIVATIVES OF 4 (-2-PHENYLTHIAZOL-5-yl) -1,4-DIAZABICYCLO- [3.2.2] NONANE, THEIR PREPARATION AND THEIR THERAPY APPLICATION
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
FR2832713B1 (en) * 2001-11-23 2004-02-13 Sanofi Synthelabo DERIVATIVES OF 4- (1,3,4-THIADIAZOL-2-YL) -1,4-DIAZABICYCLO [3.2.2] NONANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Also Published As

Publication number Publication date
MXPA05003344A (en) 2005-11-23
NO20052124L (en) 2005-06-29
NO20052124D0 (en) 2005-04-29
HK1081954A1 (en) 2006-05-26
CN1684965A (en) 2005-10-19
SI1551835T1 (en) 2007-06-30
JP2006503062A (en) 2006-01-26
CN1326857C (en) 2007-07-18
JP4711391B2 (en) 2011-06-29
RU2323218C2 (en) 2008-04-27
PT1551835E (en) 2007-03-30
IL166821A (en) 2009-06-15
IL166821A0 (en) 2006-01-15
KR20050062575A (en) 2005-06-23
RU2005105048A (en) 2005-11-20
IS7829A (en) 2005-04-28

Similar Documents

Publication Publication Date Title
BR0313153A (en) Quinuclidine derivative, pharmaceutical composition, use of a quinuclidine derivative, and method of treating, preventing or alleviating a disease or disorder or condition of a living animal body
BRPI0506881A (en) diazabicyclically arila derivative, pharmaceutical composition, use of a diazabicyclically arila derivative, and, method of treatment, prevention or alleviation of a disease or disorder or condition of a living animal body
BRPI0507296A (en) urea derivative, pharmaceutical composition, use of a urea derivative, and method of treatment, prevention or alleviation of a disease or disorder or condition of a living animal body
Levin et al. AR-R 17779, an α7 nicotinic agonist, improves learning and memory in rats
BR0312216A (en) Compound, process for producing a compound, pharmaceutical composition, use of the compound, method for treating a subject suffering from a disease or condition and product combination
BRPI0506890A (en) diazabicyclically arila derivative, pharmaceutical composition, use of a diazabicyclically arila derivative, and, method of treatment, prevention or alleviation of a disease, disorder or condition of a living animal body
JP2002522390A (en) Pharmaceutical composition for prevention and treatment of central nervous system diseases
BRPI0412382A (en) compound, method for the discovery of novel medicinal compounds which bind to and modulate the activity, by agonism, partial agonism, or antagonism, of the nicotinic alpha7 acetylcholine receptor, method of treatment or prophylaxis of a human disease or condition, method for treatment of jetlag, inducing smoking cessation, nicotine addiction, withdrawal, pain, and for ulcerative colitis, pharmaceutical composition, and, method of treating or preventing a condition or disorder arising from nicotinic acetylcholine receptor neurotransmission dysfunction in a mammal, and, use of a compound
BRPI0416212A (en) pyridazinone derivative, pharmaceutical composition, use of the derivative, method for treating a subject afflicted with a condition or disease amenable to phosphodiesterase 4 inhibition and combination product
KR19990067527A (en) Use of efinastin for the treatment of pain
JP2020516591A (en) Pharmaceutical composition containing MOR agonist and KOR agonist, and use thereof
BR0309167A (en) Compound, process for producing a compound, pharmaceutical composition, use of the compound, method for treating a subject affected by a pathological condition or disease and combination product
DK1551835T3 (en) Newly known 1,4-diazabicycloalkane derivatives, their preparation and use
BRPI0314308B8 (en) opioid antagonists, their uses, and pharmaceutical composition
DK2032575T3 (en) Newly known 1,4-diaza-bicyclo [3.2.2] nonyl-oxadiazolyl derivative and its medical use
BRPI0507786A (en) compound and pharmaceutically acceptable salts thereof, pharmaceutical formulation, use of a compound, method of treating a disease, and process for preparing compounds
TW201924681A (en) Combination use of KOR agonist and MOR agonist in the preparation of a medicament for the treatment of pain
BR0314183A (en) 1,4-Diazabicycloalkane derivatives, any of their enantiomers or any mixture of their enantiomers, or a pharmaceutically acceptable addition salt or n-oxide thereof, pharmaceutical composition, use of said compound, any of its enantiomers or any mixture of their enantiomers, or a pharmaceutically acceptable addition salt thereof, and, method of treating, preventing or alleviating a disease or disorder or condition of a living animal body
CA2582436A1 (en) Combinations of nicotinic acetylcholine alpha 7 receptor agonists
IL192287A0 (en) Pharmaceutical compositions and methods for use
BRPI0411608A (en) 8-aza-bicyclo [3.2.1] octane derivative, pharmaceutical composition, use of the compound, and method of treating, preventing or alleviating a disease, disorder or condition of a living animal organism
BRPI0409576A (en) arylvinylazacycloalkane compounds and methods for their preparation and use
BRPI0409884A (en) compounds, pharmaceutical compositions, method for treating or porphyxia of diseases, and uses of compounds and one or more compounds in combination with other pharmacologically active compounds
Mahesh et al. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods
BRPI0809873A2 (en) "compound, process for preparing the compound, method for treating a central nervous system disorder, pharmaceutical composition, use of the compound, method for testing antagonists and antagonists with 5-th6 receptor selectivity and method of treatment"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]